Commonwealth Fund January 24, 2020
Toplines
In 2019, the Senate, House, and Trump administration all took action on drug-pricing reform but failed to enact a major law
There is reason for optimism that Congress and the administration can pass drug-pricing legislation before national elections in November
Last year started with enthusiasm, tinged with some skepticism, for Congress and the president to pass comprehensive drug-pricing reform with bipartisan support. The year ended without a major bill-signing ceremony, and conventional wisdom holds that Washington can’t get anything done. But a closer look at drug-pricing activity in 2019 suggests reason for optimism.
First, two long-debated bills tangential to drug cost were enacted in 2019. The CREATES Act passed in December; it ends anticompetitive practices by some brand-name pharmaceutical...
Today's Sponsors
Today's Sponsor